DE60237594D1 - Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans - Google Patents

Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans

Info

Publication number
DE60237594D1
DE60237594D1 DE60237594T DE60237594T DE60237594D1 DE 60237594 D1 DE60237594 D1 DE 60237594D1 DE 60237594 T DE60237594 T DE 60237594T DE 60237594 T DE60237594 T DE 60237594T DE 60237594 D1 DE60237594 D1 DE 60237594D1
Authority
DE
Germany
Prior art keywords
mrna expression
pioglitazone
treatment
promoting agent
arteriosclerosis obliterans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237594T
Other languages
German (de)
English (en)
Inventor
Yasuo Sugiyama
Hiromitsu Fuse
Masao Hirakata
Ryuichi Tozawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60237594D1 publication Critical patent/DE60237594D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60237594T 2001-04-25 2002-04-24 Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans Expired - Lifetime DE60237594D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001128222 2001-04-25
PCT/JP2002/004072 WO2002087580A1 (fr) 2001-04-25 2002-04-24 Promoteurs d'expression d'abc

Publications (1)

Publication Number Publication Date
DE60237594D1 true DE60237594D1 (de) 2010-10-21

Family

ID=18976958

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237594T Expired - Lifetime DE60237594D1 (de) 2001-04-25 2002-04-24 Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans

Country Status (6)

Country Link
US (1) US20040077689A1 (fr)
EP (1) EP1382336B1 (fr)
AT (1) ATE480236T1 (fr)
CA (1) CA2445322C (fr)
DE (1) DE60237594D1 (fr)
WO (1) WO2002087580A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
NZ531346A (en) * 2001-08-28 2005-10-28 Sankyo Co Medicinal compositions containing angiotensin II receptor antagonist
WO2006004030A1 (fr) * 2004-07-02 2006-01-12 Sankyo Company, Limited Inhibiteur de la production de facteur tissulaire
KR101021828B1 (ko) 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
CA2621164A1 (fr) * 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Derive ayant une activite agoniste vis-a-vis du ppar
US8337896B2 (en) * 2007-12-13 2012-12-25 Kyushu University, National University Corporation Drug-containing nanoparticles
US20160199497A1 (en) * 2014-09-10 2016-07-14 Purdue Research Foundation Cholesterol Ester-Depleting Nanomedicine for Non-toxic Cancer Chemotherapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
NZ332136A (en) * 1996-04-04 1999-08-30 Sankyo Co Phenylalkylcarboxylic acid derivatives useful for treating hyperglycemia
WO1998005331A2 (fr) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention ou traitement de diabetes non insulinodependants ou de maladies cardiovasculaires avec des modulateurs ppar
JPH1072371A (ja) * 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
US6300364B1 (en) * 1997-07-24 2001-10-09 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US5893865A (en) * 1997-09-23 1999-04-13 Baxter Research Medical, Inc. Apparatus and method for improved aortic incision
WO1999032465A1 (fr) * 1997-12-19 1999-07-01 Merck & Co., Inc. Derives d'arylthiazolidinedione
DE69919156T2 (de) * 1998-05-11 2005-11-03 Takeda Pharmaceutical Co. Ltd. Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung
WO1999059586A1 (fr) * 1998-05-19 1999-11-25 Regents Of The University Of California Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
AU7115300A (en) * 1999-09-08 2001-04-10 Glaxo Group Limited Oxazole ppar antagonists
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
HUP0203837A2 (hu) * 1999-11-10 2003-03-28 Takeda Chemical Industries, Ltd. Testtömegnövekedést gátló szerek
BR0015466A (pt) * 1999-11-10 2002-08-06 Takeda Chemical Industries Ltd Composto, prodroga, composição farmacêutica, agentes para evitar ou tratar diabetes mellitus, hiperlipidemia e toler ncia à glicose prejudicada, para regular a função do receptor relacionado a retinóide e para melhorar a resistência à insulina e uso de um composto
WO2001034579A1 (fr) * 1999-11-10 2001-05-17 Takeda Chemical Industries, Ltd. Derives d'acide alcoxyiminoalcanoique
BR0109107A (pt) * 2000-03-09 2002-12-03 Aventis Pharma Gmbh Usos terapêuticos de mediadores ppar

Also Published As

Publication number Publication date
WO2002087580A1 (fr) 2002-11-07
EP1382336B1 (fr) 2010-09-08
CA2445322A1 (fr) 2002-11-07
ATE480236T1 (de) 2010-09-15
US20040077689A1 (en) 2004-04-22
EP1382336A1 (fr) 2004-01-21
CA2445322C (fr) 2011-06-14
EP1382336A4 (fr) 2007-08-08

Similar Documents

Publication Publication Date Title
DE60211891D1 (de) Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
DE60036169D1 (de) Methoden zur Behandlung der Hautpigmentierung
DE60229041D1 (de) Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen
DE60328517D1 (de) Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60335997D1 (de) Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE476924T1 (de) Vorrichtungen zur behandlung von empfänglicher plaque
ATE302017T1 (de) Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE60012774D1 (de) Zusammensetzungen mit hydroxyeicosatetraensäure derivate und verfahren zur verwendung zur behandlung des trockenen auges
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE60013266D1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60021908D1 (de) Hydroxyeicosatetraenoatsalze, zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
DE60237594D1 (de) Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60001255T2 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen